Art. -Nr.: HY-13502

Mitoxantrone

(Synonyms: Mitozantrone; NSC 301739)

46 Cited Publications

Kundenbewertung

Based on 46 publication(s) in Google Scholar

Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity. Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.58%
CAS. Nr.: 65271-80-9
Formel: C₂₂H₂₈N₄O₆
Molecular Weight:444.48

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Mitoxantrone Chemical Structure

CAS. Nr.: 65271-80-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (46)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity^[1]^[2]^[3]^[4]. Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively^[5].

IC₅₀ & Target^[1]^[2]

PKC

8.5 μM (IC₅₀)

Topoisomerase II

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Alle PKC Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	7.8 nM Compound: Mitoxantrone	Antiproliferative activity against human 2008 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay Antiproliferative activity against human 2008 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	[PMID: 31465686]
A2780	IC₅₀	25.1 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI) In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)	[PMID: 10479282]
A2780	IC₅₀	6.11 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780 In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780	[PMID: 10479282]
A2780	IC₅₀	0.00055 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs	[PMID: 9371240]
A2780	IC₅₀	0.55 nM Compound: mitoxantrone	Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs	[PMID: 9371240]
A2780	IC₅₀	0.00055 μM Compound: Mitoxantrone	Concentration required to inhibit A2780-cell growth by 50% Concentration required to inhibit A2780-cell growth by 50%	[PMID: 9703471]
A2780	IC₅₀	0.55 nM Compound: Mitoxantrone	Concentration required to inhibit A2780-cell growth by 50% Concentration required to inhibit A2780-cell growth by 50%	[PMID: 9703471]
A2780	IC₅₀	5.5 μM Compound: Mitoxantrone	Compound was evaluated for cytotoxicity against A2780 cell lines. Compound was evaluated for cytotoxicity against A2780 cell lines.	10.1016/0960-894X(96)00130-8
A-375	IC₅₀	111.5 nM Compound: Mitoxantrone	Cytotoxicity against human A375 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human A375 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
A-375	IC₅₀	2.6 x 10^-8 M Compound: Mitoxantrone	Inhibitory activity against human tumor cell line A0375 melanoma. Inhibitory activity against human tumor cell line A0375 melanoma.	[PMID: 7853345]
A549	IC₅₀	3 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	0.3 μM Compound: Mitoxantrone	Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line	[PMID: 12031316]
A549	IC₅₀	0.3 μM Compound: Mitoxantrone	In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis) In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)	[PMID: 12036369]
A549	IC₅₀	8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19615900]
A549	GI₅₀	8.3 μM Compound: Mitoxantrone	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 20153184]
A549	IC₅₀	7.83 μM Compound: MX	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 21354791]
A549	IC₅₀	7.8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21458279]
A549	IC₅₀	7.8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 21507644]
A549	IC₅₀	15.7 μg/mL Compound: Mitoxantrone	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26599534]
A549	IC₅₀	0.036 nM Compound: Mitoxantrone	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30485090]
A549	IC₅₀	7.25 μM Compound: Table S1, R142C2	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30684866]
A549	IC₅₀	0.07 μM Compound: Mitoxantrone	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth Antiproliferative activity against human A549 cells assessed as inhibition of cell growth	[PMID: 35931243]
A549	IC₅₀	3.1 nM Compound: Mitoxantrone	Tested against A549 lung carcinoma in the sulforhodamine B assay. Tested against A549 lung carcinoma in the sulforhodamine B assay.	[PMID: 8648600]
A549	IC₅₀	3.1 nM Compound: mitoxantrone	Activity against A549 cancer cell line. Activity against A549 cancer cell line.	[PMID: 8960558]
A549	IC₅₀	25.3 μg/mL Compound: Mito	Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay	10.1007/s00044-012-0325-2
Bel-7402	IC₅₀	116.6 nM Compound: Mitoxantrone	Cytotoxicity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
Bone marrow cell	GI₅₀	7 μM Compound: Mitoxantrone	Growth inhibition of human bone marrow cells Growth inhibition of human bone marrow cells	[PMID: 29995404]
C6	IC₅₀	11 μg/mL Compound: Mitoxantrone	Cytotoxicity against rat C6 cells after 24 hrs by MTT assay Cytotoxicity against rat C6 cells after 24 hrs by MTT assay	[PMID: 26599534]
C6	IC₅₀	10.9 μg/mL Compound: Mito	Cytotoxicity against Rattus norvegicus (rat) C6 cells after 24 hr by MTT assay Cytotoxicity against Rattus norvegicus (rat) C6 cells after 24 hr by MTT assay	10.1007/s00044-012-0325-2
Caco-2	IC₅₀	>10 μM Compound: 1	Cytotoxicity against NAE-knockdown human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against NAE-knockdown human Caco2 cells after 72 hrs by MTT assay	[PMID: 29232579]
Caco-2	IC₅₀	1.4 μM Compound: 1	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 29232579]
Cancer cell lines	IC₅₀	0.75 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human H460M cancer cell line was determined after 144 hr Cytotoxicity against human H460M cancer cell line was determined after 144 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	0.85 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human H460M cancer cell line was determined after 1 hr Cytotoxicity against human H460M cancer cell line was determined after 1 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	6.8 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	75 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human PC3 cancer cell line was determined after 1 hr Cytotoxicity against human PC3 cancer cell line was determined after 1 hr	[PMID: 15456268]
CCD 19Lu	IC₅₀	>160 nM Compound: Mitoxantrone	Cytotoxicity in human CCD-19Lu cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human CCD-19Lu cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30108778]
CCRF-CEM	IC₅₀	3.6 μM Compound: Mitoxantrone	Cytotoxicity in human leukemic CCRF-CEM cells. Cytotoxicity in human leukemic CCRF-CEM cells.	[PMID: 14667232]
CCRF-CEM	IC₅₀	0.036 μM Compound: mitoxantrone	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CH1	IC₅₀	0.00265 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit CH1 cell growth by 50% Cytotoxic potency required to inhibit CH1 cell growth by 50%	[PMID: 9371240]
CH1	IC₅₀	0.00265 μM Compound: Mitoxantrone	Concentration required to inhibit CH1-cell growth by 50% Concentration required to inhibit CH1-cell growth by 50%	[PMID: 9703471]
CHO	IC₅₀	22.5 μM Compound: mitoxantrone	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
Daudi	IC₅₀	0.005 μM Compound: Mit	Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay	[PMID: 25998504]
DU-145	IC₅₀	5.6 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145 In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145	[PMID: 10479282]
G-361	IC₅₀	0.00065 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit G-361 cell growth by 50% Cytotoxic potency required to inhibit G-361 cell growth by 50%	[PMID: 9371240]
G-361	IC₅₀	0.65 nM Compound: mitoxantrone	Cytotoxic potency required to inhibit G-361 cell growth by 50% Cytotoxic potency required to inhibit G-361 cell growth by 50%	[PMID: 9371240]
H22	IC₅₀	187 nM Compound: Mitoxantrone	Dark toxicity against mouse H22 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Dark toxicity against mouse H22 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
HaCaT	IC₅₀	3.9 μM Compound: Mitoxantrone	Cytotoxicity against human HaCaT cells by Cell titre-blue assay Cytotoxicity against human HaCaT cells by Cell titre-blue assay	[PMID: 26684177]
HCC78	IC₅₀	13.83 nM Compound: Mitoxantrone	Cytotoxicity in human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30108778]
HCT-116	IC₅₀	110 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr	[PMID: 15456268]
HCT-116	IC₅₀	5.8 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr	[PMID: 15456268]
HCT-116	IC₅₀	3.96 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20951582]
HCT-116	IC₅₀	0.022 μM Compound: Mx	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
HCT-116	IC₅₀	7.2 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 21458279]
HCT-116	IC₅₀	7.2 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21507644]
HCT-116	IC₅₀	0.025 μM Compound: Mit	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25998504]
HCT-116	IC₅₀	1.61 μM Compound: Mitoxantrone	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29407981]
HEK293	IC₅₀	0.4 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	[PMID: 23241029]
HEK293	IC₅₀	0.53 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	0.53 μM Compound: mitoxantrone	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	0.83 μM Compound: mitoxantrone	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	43.9 μM Compound: mitoxantrone	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	60.5 μM Compound: mitoxantrone	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	73.3 μM Compound: mitoxantrone	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	10 nM Compound: Mitoxantrone	Cytotoxicity against HEK293 cells after 72 hrs by MTT assay Cytotoxicity against HEK293 cells after 72 hrs by MTT assay	[PMID: 24611893]
HEK293	IC₅₀	26.6 nM Compound: Mitoxantrone	Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay	[PMID: 24611893]
HEK293	IC₅₀	11.7 nM Compound: Mitoxantrone	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	[PMID: 31465686]
HEK293	IC₅₀	0.04 μM Compound: MX	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 36780419]
HEK293	IC₅₀	1.72 μM Compound: MX	Cytotoxicity against human HEK293 cells expressing ABCG2 assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HEK293 cells expressing ABCG2 assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 36780419]
HEK-293T	IC₅₀	<0.1 μM Compound: mitoxantrone	Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay	[PMID: 18754611]
HeLa	IC₅₀	<0.1 μM Compound: mitoxantrone	Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay	[PMID: 18754611]
HeLa	IC₅₀	0.044 μM Compound: Mit	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25998504]
HeLa	IC₅₀	2.35 μM Compound: Mitoxantrone	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29407981]
HeLa	EC₅₀	0.55 μg/mL Compound: 4	Effective concentration required to inhibit by 50% the growth of HeLa S3 cells Effective concentration required to inhibit by 50% the growth of HeLa S3 cells	[PMID: 3172129]
HeLa	IC₅₀	0.04 μM Compound: Mitoxantrone	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth	[PMID: 35931243]
HepG2	IC₅₀	11.05 μM Compound: Mitoxantrone	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24794747]
HepG2	IC₅₀	18.6 μM Compound: Mitoxantrone	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29407981]
HepG2	IC₅₀	15.33 μM Compound: MTZ	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
HL-60	IC₅₀	3.35 μM Compound: mitoxantrone	Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC50 Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC50	[PMID: 10377219]
HL-60	IC₅₀	0.81 nM Compound: Mitoxantrone	Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound) Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound)	[PMID: 10479282]
HL-60	IC₅₀	0.29 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 10843567]
HL-60	GI₅₀	0.01 μM Compound: mitoxantrone	Growth inhibition of human HL60 cells by Almar blue assay Growth inhibition of human HL60 cells by Almar blue assay	[PMID: 17418582]
HL-60	GI₅₀	0.33 nM Compound: MX, mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 17962028]
HL-60	IC₅₀	0.063 μM Compound: MX, mitoxantrone	Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs	[PMID: 18507368]
HL-60	IC₅₀	6.3 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19615900]
HL-60	GI₅₀	0.192 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	IC₅₀	6.8 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19926279]
HL-60	GI₅₀	7.8 μM Compound: Mitoxantrone	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 20153184]
HL-60	IC₅₀	7.5 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20951582]
HL-60	IC₅₀	0.063 μM Compound: MX	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	1.51 μM Compound: MX	Cytotoxicity against human HL60/MX2 cells after 72 hrs Cytotoxicity against human HL60/MX2 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	8.1 μM Compound: MX	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 21354791]
HL-60	IC₅₀	0.063 μM Compound: MTX, NOVANTRONE	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 21439821]
HL-60	IC₅₀	7.9 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 21458279]
HL-60	IC₅₀	8.2 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 21507644]
HL-60	IC₅₀	0.016 μM Compound: mitoxantrone	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.0025 μM Compound: Mitoxantrone	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 22944121]
HL-60	IC₅₀	4 nM Compound: MITO	Cytotoxicity against human HL60 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HL60 cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
HL-60	IC₅₀	4 nM Compound: MITO	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 29945793]
HL-60	IC₅₀	0.024 nM Compound: Mitoxantrone	Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay	[PMID: 30485090]
HL60/MX2	GI₅₀	26 nM Compound: MX, mitoxantrone	Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay	[PMID: 17962028]
HL60/MX2	IC₅₀	1.51 μM Compound: MX, mitoxantrone	Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs	[PMID: 18507368]
HL60/MX2	GI₅₀	4.42 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL60/MX2	IC₅₀	1.51 μM Compound: MTX, NOVANTRONE	Cytotoxicity against human HL60/MX2 cells Cytotoxicity against human HL60/MX2 cells	[PMID: 21439821]
HL60/MX2	IC₅₀	0.561 μM Compound: Mitoxantrone	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	[PMID: 22944121]
HL60/MX2	IC₅₀	148 nM Compound: MITO	Cytotoxicity against human HL60/MX2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HL60/MX2 cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
HL60/MX2	IC₅₀	148 nM Compound: MITO	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	[PMID: 29945793]
HT-1080	IC₅₀	6.6 x 10^-8 M Compound: Mitoxantrone	Inhibitory activity against human tumor cell line HT1080. Inhibitory activity against human tumor cell line HT1080.	[PMID: 7853345]
HT-29	IC₅₀	0.01 μM Compound: Mitoxantrone	In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line	[PMID: 10411474]
HT-29	IC₅₀	19.6 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29 In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29	[PMID: 10479282]
HT-29	IC₅₀	2025 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx	[PMID: 10479282]
HT-29	IC₅₀	0.01 μM Compound: MX	Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line	[PMID: 11563932]
HT-29	IC₅₀	10 nM Compound: Mitoxantrone (Mx)	In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line. In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.	[PMID: 11806721]
HT-29	IC₅₀	8 μM Compound: Mitoxantrone	Inhibitory concentration of compound against proliferation of colon carcinoma HT-29 cell line Inhibitory concentration of compound against proliferation of colon carcinoma HT-29 cell line	[PMID: 12031316]
HT-29	IC₅₀	8 μM Compound: Mitoxantrone	In vitro cytotoxic activity against human colon HT-29 cell line ( standard deviation in parenthesis) In vitro cytotoxic activity against human colon HT-29 cell line ( standard deviation in parenthesis)	[PMID: 12036369]
HT-29	IC₅₀	10 nM Compound: MX (Mitoxantrone)	Cytotoxicity is determined as the concentration required to inhibit the growth of human colon adenocarcinoma (HT-29) cell line Cytotoxicity is determined as the concentration required to inhibit the growth of human colon adenocarcinoma (HT-29) cell line	[PMID: 15456268]
HT-29	IC₅₀	0.02 μM Compound: Mitoxantrone (Mx)	In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells	[PMID: 16169719]
HT-29	IC₅₀	0.025 μM Compound: Mx	Antiproliferative activity against HT29 cells by MTT assay after 72 hrs Antiproliferative activity against HT29 cells by MTT assay after 72 hrs	[PMID: 16824751]
HT-29	IC₅₀	8.7 μM Compound: Mitoxantrone	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19615900]
HT-29	GI₅₀	8.9 μM Compound: Mitoxantrone	Growth inhibition of human HT-29 cells by MTT assay Growth inhibition of human HT-29 cells by MTT assay	[PMID: 20153184]
HT-29	IC₅₀	21.65 μM Compound: Mitoxantrone	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29407981]
HT-29	IC₅₀	1.7 x 10^-8 M Compound: Mitoxantrone	Inhibitory activity against human tumor cell line HT-29. Inhibitory activity against human tumor cell line HT-29.	[PMID: 7853345]
HT-29	IC₅₀	0.01 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs	[PMID: 9371240]
Ishikawa	IC₅₀	0.01 μM Compound: Mit	Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay	[PMID: 25998504]
K562	IC₅₀	133.5 nM Compound: Mitoxantrone	Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound) Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound)	[PMID: 10479282]
K562	IC₅₀	7.06 nM Compound: Mitoxantrone	Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound) Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound)	[PMID: 10479282]
K562	IC₅₀	0.0334 μg/mL Compound: mitoxantrone	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 10843567]
K562	IC₅₀	2 μg/mL Compound: mitoxanthrone	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 12027731]
K562	IC₅₀	0.0026 μM Compound: mitoxantrone	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.42 μM Compound: Mitoxantrone	Growth inhibition of human K562 cells after 72 hrs by MTS method Growth inhibition of human K562 cells after 72 hrs by MTS method	[PMID: 18258442]
K562	IC₅₀	0.51 μM Compound: mitoxantrone	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	4.55 μM Compound: Mitoxantrone	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29407981]
K562	IC₅₀	2.35 μM Compound: MTZ	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
K562	IC₅₀	0.14 μM Compound: Mitoxantrone	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth Antiproliferative activity against human K562 cells assessed as inhibition of cell growth	[PMID: 35931243]
KB	EC₅₀	0.355 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay	[PMID: 21458262]
KB	EC₅₀	0.36 μM Compound: mitoxantrone	Antiproliferative activity against human KB/HeLa cells after 48 hrs Antiproliferative activity against human KB/HeLa cells after 48 hrs	[PMID: 23395656]
KB	EC₅₀	0.42 μM Compound: Mitoxantrone	Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
L1210	IC₅₀	11.4 nM Compound: Mitoxantrone	Compound was tested in vitro for cytotoxicity against L1210 murine cell line (48 hr exposure to compound) Compound was tested in vitro for cytotoxicity against L1210 murine cell line (48 hr exposure to compound)	[PMID: 10479282]
L1210	IC₅₀	10 nM Compound: mitoxantrone	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	39 nM Compound: mitoxantrone	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	0.04 μM Compound: Mitoxantrone	Inhibitory concentration of compound against proliferation of murine leukemia L1210 cell line Inhibitory concentration of compound against proliferation of murine leukemia L1210 cell line	[PMID: 12031316]
L1210	IC₅₀	0.1 μM Compound: Mitoxantrone	In vitro cytotoxicity against mouse leukemia L1210 cell lines In vitro cytotoxicity against mouse leukemia L1210 cell lines	[PMID: 15341949]
L1210	IC₅₀	0.002 μM Compound: Mitoxantrone	In vitro extracellular concentration required to reduce cell population to 50% against L1210 leukemia cells In vitro extracellular concentration required to reduce cell population to 50% against L1210 leukemia cells	[PMID: 1573635]
L1210	IC₅₀	0.077 μM Compound: Mitoxantrone (Mx)	In vitro cytotoxicity against murine leukemia cell line L1210 In vitro cytotoxicity against murine leukemia cell line L1210	[PMID: 16169719]
L1210	IC₅₀	15 μM Compound: Mitoxantrone	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28222315]
L1210	EC₅₀	>5 μg/mL Compound: 4	Effective concentration required to inhibit by 50% the growth of L1210 cells Effective concentration required to inhibit by 50% the growth of L1210 cells	[PMID: 3172129]
L1210	IC₅₀	0.1 μM Compound: mitoxantrone	Dose level for 50% inhibition of L1210 cell growth was measured after 24 h. Dose level for 50% inhibition of L1210 cell growth was measured after 24 h.	[PMID: 3351863]
L1210	IC₅₀	0.1 μM Compound: mitoxantrone	Dose level for 50% inhibition of L1210 cell growth was measured after 48 hr. Dose level for 50% inhibition of L1210 cell growth was measured after 48 hr.	[PMID: 3351863]
L1210	IC₅₀	1.6 x 10^-9 M Compound: 1	In vitro for its inhibitory activity against murine L1210 leukemia In vitro for its inhibitory activity against murine L1210 leukemia	[PMID: 3397990]
L1210	IC₅₀	1.6 x 10^-9 M Compound: 5 (mitoxantrone)	Tested in vitro against murine L1210 leukemia. Tested in vitro against murine L1210 leukemia.	[PMID: 3806589]
L1210	IC₅₀	39 nM Compound: Mitoxantrone	Antitumor activity against murine L1210 resistant cell line by using MTT assay Antitumor activity against murine L1210 resistant cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	5 nM Compound: Mitoxantrone	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	0.009 μg/mL Compound: 1b (mitoxantrone)	Tested in vitro for inhibitory activity against L1210 murine leukemia Tested in vitro for inhibitory activity against L1210 murine leukemia	[PMID: 8145234]
L1210	IC₅₀	21 nM Compound: Mitoxantrone	An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line. An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.	[PMID: 8648600]
L1210	IC₅₀	39 nM Compound: Mitoxantrone	Inhibitory activity against resistant murine leukemia L1210 cell lines. Inhibitory activity against resistant murine leukemia L1210 cell lines.	[PMID: 8648600]
L1210	IC₅₀	9.7 nM Compound: Mitoxantrone	Inhibitory activity against sensitive L1210 cell lines Inhibitory activity against sensitive L1210 cell lines	[PMID: 8648600]
L1210	IC₅₀	39 nM Compound: mitoxantrone	Antitumor activity against murine leukemia L1210 cell line. Antitumor activity against murine leukemia L1210 cell line.	[PMID: 8960558]
L1210	IC₅₀	9.7 nM Compound: mitoxantrone	Antitumor activity against sensitive L1210 murine leukemia cell lines. Antitumor activity against sensitive L1210 murine leukemia cell lines.	[PMID: 8960558]
LoVo	IC₅₀	0.046 μM Compound: Mitoxantrone	In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line	[PMID: 10411474]
LoVo	IC₅₀	1.29 μM Compound: Mitoxantrone	In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line	[PMID: 10411474]
LoVo	IC₅₀	17.1 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo	[PMID: 10479282]
LoVo	IC₅₀	461 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo/Dx(RI) In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo/Dx(RI)	[PMID: 10479282]
LoVo	IC₅₀	0.023 μg/mL Compound: mitoxantrone	In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells	[PMID: 10698460]
LoVo	IC₅₀	0.62 μg/mL Compound: mitoxantrone	In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells. In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.	[PMID: 10698460]
LoVo	IC₅₀	12 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human LoVo cancer cell line was determined after 1 hr Cytotoxicity against human LoVo cancer cell line was determined after 1 hr	[PMID: 15456268]
LoVo	IC₅₀	3.3 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human LoVo cancer cell line was determined after 144 hr Cytotoxicity against human LoVo cancer cell line was determined after 144 hr	[PMID: 15456268]
LoVo	IC₅₀	5.3 x 10^-7 M Compound: Mitoxantrone	Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx. Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.	[PMID: 7853345]
LoVo	IC₅₀	9.7 x 10^-9 M Compound: Mitoxantrone	Inhibitory activity against human colon adenocarcinoma cell line LoVo. Inhibitory activity against human colon adenocarcinoma cell line LoVo.	[PMID: 7853345]
LoVo	IC₅₀	0.009 μg/mL Compound: 1b (mitoxantrone)	Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo) Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo)	[PMID: 8145234]
LoVo	IC₅₀	0.25 μg/mL Compound: 1b (mitoxantrone)	Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line	[PMID: 8145234]
LoVo	IC₅₀	0.024 μg/mL Compound: mitoxantrone	In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line. In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.	[PMID: 9876113]
LoVo	IC₅₀	0.67 μg/mL Compound: mitoxantrone	In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line. In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.	[PMID: 9876113]
MCF7	IC₅₀	41 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	72 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	9 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	0.005 μM Compound: MTXN	In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system	[PMID: 1447730]
MCF7	IC₅₀	4 μM Compound: MTXN	In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system. In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.	[PMID: 1447730]
MCF7	GI₅₀	3.93 μM Compound: MX, mitoxantrone	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 17962028]
MCF7	IC₅₀	7.1 μM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19615900]
MCF7	IC₅₀	7.1 μM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21458279]
MCF7	IC₅₀	26 nM Compound: mitoxantrone	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 25811651]
MCF7	IC₅₀	380.2 nM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
MCF7	IC₅₀	2.0 x 10^-8 M Compound: Mitoxantrone	Inhibitory activity against human tumor cell line MCF-7 breast adenocarcinoma. Inhibitory activity against human tumor cell line MCF-7 breast adenocarcinoma.	[PMID: 7853345]
MCF7	IC₅₀	41 nM Compound: Mitoxantrone	Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay. Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.	[PMID: 8648600]
MCF7	IC₅₀	72 nM Compound: Mitoxantrone	Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay. Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.	[PMID: 8648600]
MCF7	IC₅₀	8.7 nM Compound: Mitoxantrone	Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay. Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.	[PMID: 8648600]
MCF7	IC₅₀	41 nM Compound: mitoxantrone	Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line. Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.	[PMID: 8960558]
MCF7	IC₅₀	72 nM Compound: mitoxantrone	Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line. Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.	[PMID: 8960558]
MCF7	IC₅₀	8.7 nM Compound: mitoxantrone	Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line. Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.	[PMID: 8960558]
MDA-MB-231	IC₅₀	1 μM Compound: Mitoxantrone	In vitro cytotoxic activity against human breast MDA-MB-231 cell line ( standard deviation in parenthesis) In vitro cytotoxic activity against human breast MDA-MB-231 cell line ( standard deviation in parenthesis)	[PMID: 12036369]
MDA-MB-231	IC₅₀	0.96 μM Compound: mitoxantrone	Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs	[PMID: 17335189]
MDA-MB-231	IC₅₀	0.96 μM Compound: mitoxantrone	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 18296053]
MDA-MB-435	IC₅₀	0.35 nM Compound: Mitoxantrone	Antiproliferative activity against MDA435/LCC6 cells by ELISA Antiproliferative activity against MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	1442 nM Compound: Mitoxantrone	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	646 nM Compound: Mitoxantrone	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
MDCK-II	IC₅₀	0.19 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	[PMID: 23241029]
MES-SA	IC₅₀	0.003 μM Compound: Mitoxantrone (Mx)	In vitro cytotoxicity against uterine sarcoma MES-SA cells In vitro cytotoxicity against uterine sarcoma MES-SA cells	[PMID: 16169719]
MES-SA	IC₅₀	0.03 μM Compound: Mitoxantrone (Mx)	In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells	[PMID: 16169719]
MES-SA	IC₅₀	0.003 μM Compound: Mx	Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA	IC₅₀	0.012 μM Compound: Mx	Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MES-SA	IC₅₀	0.006 μM Compound: Mit	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 25998504]
MES-SA/Dx5	IC₅₀	0.028 μM Compound: Mx	Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA/Dx5	IC₅₀	0.08 μM Compound: Mx	Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MES-SA/Dx5	IC₅₀	0.073 μM Compound: Mit	Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay	[PMID: 25998504]
MKN-28	IC₅₀	0.02 μg/mL Compound: mitoxantrone	Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay	[PMID: 10843567]
MKN-45	IC₅₀	12 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr	[PMID: 15456268]
N592	IC₅₀	0.02 μM Compound: Mitoxantrone	Cytotoxicity against human small-cell lung cancer (SCLC) Cytotoxicity against human small-cell lung cancer (SCLC)	[PMID: 8258835]
NCI-H460	GI₅₀	1.29 μM Compound: MX, mitoxantrone	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 17962028]
NCI-H460	EC₅₀	0.1224 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay	[PMID: 21458262]
NCI-H460	EC₅₀	0.12 μM Compound: mitoxantrone	Antiproliferative activity against human NCI-H460 cells after 48 hrs Antiproliferative activity against human NCI-H460 cells after 48 hrs	[PMID: 23395656]
NCI-H460	EC₅₀	0.03 μM Compound: Mitoxantrone	Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
NCI-H460	IC₅₀	0.36 μM Compound: MX	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay	[PMID: 31302589]
NIH3T3	IC₅₀	42 μM Compound: Mitoxantrone	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28222315]
OVCAR-3	IC₅₀	6 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	[PMID: 10956214]
OVCAR-3	IC₅₀	5.8 nM Compound: Mitoxantrone	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	[PMID: 7699715]
OVCAR-3	IC₅₀	5.8 nM Compound: Mitoxantrone	Inhibitory activity against OVCAR-3 cell line Inhibitory activity against OVCAR-3 cell line	[PMID: 8648600]
OVCAR-3	IC₅₀	5.8 nM Compound: mitoxantrone	Antitumor activity against human ovarian OVCAR-3 cell lines. Antitumor activity against human ovarian OVCAR-3 cell lines.	[PMID: 8960558]
P388	IC₅₀	27.56 μM Compound: mitoxantrone	Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC50 Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC50	[PMID: 10377219]
P388	IC₅₀	4.3 nM Compound: Mitoxantrone	Antiproliferative activity against P388 cells by ELISA Antiproliferative activity against P388 cells by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	194 nM Compound: Mitoxantrone	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	395 nM Compound: Mitoxantrone	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
PC-3	IC₅₀	7.1 nM Compound: Mitoxantrone	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3 In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3	[PMID: 10479282]
PC-3	IC₅₀	7 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human PC3 cancer cell line was determined after 144 hr Cytotoxicity against human PC3 cancer cell line was determined after 144 hr	[PMID: 15456268]
PC-3	GI₅₀	0.78 μM Compound: MX, mitoxantrone	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 17962028]
PC-3	IC₅₀	0.29 μM Compound: Mitoxantrone	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22100139]
RPMI-8226	IC₅₀	0.03 μM Compound: MTXN	In vitro inhibition of tumor cell growth in the human myeloma 8226 system. In vitro inhibition of tumor cell growth in the human myeloma 8226 system.	[PMID: 1447730]
RPMI-8226	IC₅₀	0.18 μM Compound: MTXN	In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system. In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.	[PMID: 1447730]
SCLC	IC₅₀	0.03 μM Compound: Mitoxantrone	Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP) Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP)	[PMID: 8258835]
SF-268	GI₅₀	0.97 μM Compound: MX, mitoxantrone	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 17962028]
SF-268	EC₅₀	0.315 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay	[PMID: 21458262]
SF-268	EC₅₀	0.32 μM Compound: mitoxantrone	Antiproliferative activity against human SF268 cells after 48 hrs Antiproliferative activity against human SF268 cells after 48 hrs	[PMID: 23395656]
SGC-7901	IC₅₀	0.293 nM Compound: Mitoxantrone	Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay	[PMID: 30485090]
SK-BR-3	IC₅₀	0.016 μM Compound: Mitoxantrone	The IC50 value was measured on human breast cancer cell line SK-BR-3. The IC50 value was measured on human breast cancer cell line SK-BR-3.	[PMID: 7699696]
SK-OV-3	IC₅₀	9.8 μM Compound: Mitoxantrone	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 19615900]
SK-OV-3	GI₅₀	11 μM Compound: Mitoxantrone	Growth inhibition of human SKOV3 cells by MTT assay Growth inhibition of human SKOV3 cells by MTT assay	[PMID: 20153184]
SK-OV-3	EC₅₀	0.1207 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay	[PMID: 21458262]
SK-OV-3	EC₅₀	0.12 μM Compound: mitoxantrone	Antiproliferative activity against human SKOV3 cells after 48 hrs Antiproliferative activity against human SKOV3 cells after 48 hrs	[PMID: 23395656]
SK-OV-3	IC₅₀	0.0053 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit SKOV-3 cell growth 50% Cytotoxic potency required to inhibit SKOV-3 cell growth 50%	[PMID: 9371240]
SK-OV-3	IC₅₀	0.0053 μM Compound: Mitoxantrone	Concentration required to inhibit SKOV-3-cell growth by 50% Concentration required to inhibit SKOV-3-cell growth by 50%	[PMID: 9703471]
SK-OV-3	IC₅₀	0.0053 μM Compound: Mitoxantrone	Compound was evaluated for cytotoxicity against SCOV-3 cell lines. Compound was evaluated for cytotoxicity against SCOV-3 cell lines.	10.1016/0960-894X(96)00130-8
T cell line	IC₅₀	23.1 μM Compound: 202a; MTX	Antiviral activity against HIV-1 infected in human T cell line assessed as inhibition of DNA replication Antiviral activity against HIV-1 infected in human T cell line assessed as inhibition of DNA replication	[PMID: 34060847]
U-937	IC₅₀	6.2 μM Compound: Mitoxantrone	Cytotoxicity against human U937 cells by MTT assay Cytotoxicity against human U937 cells by MTT assay	[PMID: 19615900]
UACC-375	IC₅₀	48 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	[PMID: 10956214]
UACC-375	IC₅₀	48 nM Compound: Mitoxantrone	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	[PMID: 7699715]
UACC-375	IC₅₀	48 nM Compound: Mitoxantrone	Inhibitory activity against AUC375 cell line Inhibitory activity against AUC375 cell line	[PMID: 8648600]
UACC-375	IC₅₀	48 nM Compound: mitoxantrone	Antitumor activity against human melanoma UACC375 cell line. Antitumor activity against human melanoma UACC375 cell line.	[PMID: 8960558]
WiDr	IC₅₀	488 nM Compound: mitoxantrone	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	8 nM Compound: mitoxantrone	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	10 nM Compound: Mitoxantrone	Activity against sensitive cell line of WiDr human colon tumor Activity against sensitive cell line of WiDr human colon tumor	[PMID: 7699715]
WiDr	IC₅₀	1400 nM Compound: Mitoxantrone	Activity against resistant cell line of WiDr human colon tumor Activity against resistant cell line of WiDr human colon tumor	[PMID: 7699715]
WiDr	IC₅₀	488 nM Compound: Mitoxantrone	Tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay. Tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.	[PMID: 8648600]
WiDr	IC₅₀	8.1 nM Compound: Mitoxantrone	Tested against WiDr colon (sensitive) in the sulforhodamine B assay. Tested against WiDr colon (sensitive) in the sulforhodamine B assay.	[PMID: 8648600]
WiDr	IC₅₀	488 nM Compound: mitoxantrone	Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line. Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.	[PMID: 8960558]
WiDr	IC₅₀	8.1 nM Compound: mitoxantrone	Activity against human colon carcinoma sensitive WiDr cell line. Activity against human colon carcinoma sensitive WiDr cell line.	[PMID: 8960558]
XRS6	IC₅₀	0.01 μM Compound: mitoxantrone	Cytotoxicity against CHO cell line xrs6 Cytotoxicity against CHO cell line xrs6	[PMID: 7473578]

In Vitro

Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K_i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP^[1].
Mitoxantrone (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone is due to induction of apoptosis^[2].
Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC₅₀ values of 18 and 196 nM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mitoxantrone (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia^[4].
Mitoxantrone (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 65271-80-9
Appearance Solid
Molecular Weight 444.48
Formel C₂₂H₂₈N₄O₆
Color Dark blue to black
SMILES

O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O
Synonyms

Mitozantrone; NSC 301739
Structure Classification
- Quinones
- Anthraquinones
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (46)

All Cell Proliferation/Viability AssayApoptosis AnalysisIFWB

Sort by:

Journal Impact Factor

Adv Mater

Dismantlable Coronated Nanoparticles for Coupling the Induction and Perception of Immunogenic Cell Death. [Abstract]

2024 Apr 21:e2313097. PMID: 38643386
Light Sci Appl

Dynamic synthetic-scanning photoacoustic tracking monitors hepatic and renal clearance pathway of exogeneous probes in vivo. [Abstract]

2024 Oct 31;13(1):304. PMID: 39482292
Nat Cell Biol

Mammalian IRE1α dynamically and functionally coalesces with stress granules. [Abstract]

2024 Jun;26(6):917-931. PMID: 38714852

Mitoxantrone purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]

HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).

Mitoxantrone purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]

HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).
Mol Cell

Genome-scale exon perturbation screens uncover exons critical for cell fitness. [Abstract]

2024 Jun 18:S1097-2765(24)00447-7. PMID: 38917794
Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
J Am Chem Soc

Target Profiling of an Iridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. [Abstract]

2022 Jun 15;144(23):10407-10416. PMID: 35658433
Exp Mol Med

PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. [Abstract]

2025 Nov;57(11):2559-2573. PMID: 41254241

Mitoxantrone purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Nov;57(11):2559-2573. [Abstract]

The USP11 inhibitor Mitoxantrone (5-20 μM; 24 h) was treated to A549 (western blotting for EGFR) cells. The EGFR protein levels were assessed by western blotting using an anti-EGFR antibody.
J Exp Clin Cancer Res

CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways. [Abstract]

2025 Aug 5;44(1):228. PMID: 40764945

Mitoxantrone purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]

U87-MG and U251 cells with stable CSRP2 overexpression (CSRP2) were treated with or without 0.5 µM Mitoxantrone (MTO) for indicated time periods and the cell proliferation was analyzed. Cells transfected with control vector (NC) were used as a negative control. Two-way ANOVA with Sidak’s post hoc test, n = 6 per group for U87-MG and U251.

Mitoxantrone purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]

U87-MG and U251 cells with stable CSRP2 overexpression were treated with 0.5 µM Mitoxantrone (MTO) for 48 h and cell apoptosis was measured by flow cytometry
J Control Release

A personalized vaccine combining immunogenic cell death-induced cells and nanosized antigens for enhanced antitumor immunity. [Abstract]

2024 Nov 12:376:1271-1287. PMID: 39515613
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. [Abstract]

2024 Feb 20;5(2):101388. PMID: 38262412
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587
Int J Biol Sci

ERK-mediated Cytoplasmic Retention of USP11 Contributes to Breast Cancer Cell Proliferation by Stabilizing Cytoplasmic p21. [Abstract]

2022 Mar 21;18(6):2568-2582. PMID: 35414784
Cell Death Dis

USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. [Abstract]

2025 Dec 19;16(1):894. PMID: 41419456
Int J Biol Macromol

I-motif formation in the promoter region of the B-MYB proto-oncogene. [Abstract]

2025 Jan 9:139582. PMID: 39798757
Acta Pharmacol Sin

USP11 promotes renal tubular cell pyroptosis and fibrosis in UUO mice via inhibiting KLF4 ubiquitin degradation. [Abstract]

2025 Jan;46(1):159-170. PMID: 39147900
Acta Pharmacol Sin

Deubiquitinating enzyme USP11 promotes renal tubular cell senescence and fibrosis via inhibiting the ubiquitin degradation of TGF-β receptor II. [Abstract]

2023 Mar;44(3):584-595. PMID: 36045219
EMBO Mol Med

Targeting USP11 regulation by a novel lithium-organic coordination compound improves neuropathologies and cognitive functions in Alzheimer transgenic mice. [Abstract]

2024 Nov;16(11):2856-2881. PMID: 39394468
Drug Deliv

Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels. [Abstract]

2022 Dec;29(1):2561-2578. PMID: 35938558
Talanta

High-throughput BCRP inhibitors screening system based on styrene maleic acid polymer membrane protein stabilization strategy and surface plasmon resonance biosensor. [Abstract]

2024 Jul 1:274:125987. PMID: 38552478
Biochem Pharmacol

Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]

2026 Mar 15:249:117903. PMID: 41846011
J Enzyme Inhib Med Chem

Identification of chemical scaffolds for targeting ubiquitin-specific protease 11 (USP11) through high-throughput virtual screening. [Abstract]

2025 Dec;40(1):2518191. PMID: 40588719
Int J Mol Sci

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals. [Abstract]

2026 Mar 11;27(6):2587. PMID: 41898448
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Int J Mol Sci

Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer. [Abstract]

2025 Apr 17;26(8):3790. PMID: 40332396
Cell Oncol (Dordr)

Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. [Abstract]

2020 Dec;43(6):1099-1116. PMID: 32710433
RSC Adv

Novel self-assembled metal-phenolic nanoplatforms for triple-negative breast cancer treatment: photothermal-chemotherapy/ferroptosis synergy inducing immunogenic cell death. [Abstract]

2025 Aug 15;15(35):28965-28983. PMID: 40861997
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancers

Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]

2020 Aug 4;12(8):2169. PMID: 32759815
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Drug Metab Dispos

Identification of selective substrates and inhibitors of the major human renal uptake transporters. [Abstract]

2025 Mar;53(3):100046. PMID: 40024137
RSC Med Chem

Biological assessments of novel ultrasound-synthesized 2-arylbenzimidazole derivatives: antiproliferative and antibacterial effects. [Abstract]

2025 Apr 30;16(7):3197-3212. PMID: 40352670
Med Oncol

Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells. [Abstract]

2020 Nov 19;37(12):116. PMID: 33215275
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
ChemMedChem

Benzoxazole-Acrylonitriles: Dual Bioactivity and DNA Binding from a Sustainable Synthetic Approach. [Abstract]

2025 Oct 6;20(19):e202500429. PMID: 40983325
BMC Cancer

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor. [Abstract]

2025 Jan 7;25(1):24. PMID: 39773145
BMC Cancer

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells. [Abstract]

2021 Oct 13;21(1):1101. PMID: 34645397
J Pharm Pharmacol

An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation. [Abstract]

2022 Jan 5;74(1):41-56. PMID: 34986225
Pharm Dev Technol

A promising dual-drug targeted delivery system in cancer therapy: nanocomplexes of folate-apoferritin-conjugated cationic solid lipid nanoparticles. [Abstract]

2021 Jul;26(6):673-681. PMID: 33896342
EJHaem

Adipocytes Impair Mitoxantrone Cytotoxicity Against Acute Lymphoblastic Leukemia. [Abstract]

2025 Aug 30;6(5):e70140. PMID: 40896243
University of Bonn

2025 Feb.
Patent

US20240307414A1.
University of California, Irvine

2024.
bioRxiv

2024 September 07.
bioRxiv

2023 Jan 13.
Research Square Print

November 28th, 2022.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 35 mg/mL (78.74 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2498 mL

11.2491 mL

22.4982 mL

5 mM

0.4500 mL

2.2498 mL

4.4996 mL

10 mM

0.2250 mL

1.1249 mL

2.2498 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[3]

The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10^-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Mice: Mitoxantrone is tested for antitumor activity against experimental tumors in mice and the results are compared with those of seven antitumor antibiotics. The drugs are given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone is given IP at the optimal dose (1.6 mg/kg/day; as a free base)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief]

[2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief]

[3]. Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8. [Content Brief]

[4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief]

[5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2498 mL	11.2491 mL	22.4982 mL	56.2455 mL
	5 mM	0.4500 mL	2.2498 mL	4.4996 mL	11.2491 mL
	10 mM	0.2250 mL	1.1249 mL	2.2498 mL	5.6245 mL
	15 mM	0.1500 mL	0.7499 mL	1.4999 mL	3.7497 mL
	20 mM	0.1125 mL	0.5625 mL	1.1249 mL	2.8123 mL
	25 mM	0.0900 mL	0.4500 mL	0.8999 mL	2.2498 mL
	30 mM	0.0750 mL	0.3750 mL	0.7499 mL	1.8748 mL
	40 mM	0.0562 mL	0.2812 mL	0.5625 mL	1.4061 mL
	50 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1249 mL
	60 mM	0.0375 mL	0.1875 mL	0.3750 mL	0.9374 mL

Mitoxantrone

46 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Mitoxantrone

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

TGF-beta/Smad Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Cytoskeleton Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Orthopoxvirus Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Chinese Baijiu Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Mitoxantrone

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Alle PKC Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (46)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Mitoxantrone Related Classifications

Art. -Nr.: HY-13502